Literature DB >> 4039976

Effects of combined treatments of cis-diamminedichloroplatinum(II), 5-fluorouracil, and X-rays on growth of human cancer nodules maintained in continuous organotypic culture.

R Beaupain, C Dionet.   

Abstract

The effectiveness of combined treatments of cis-diamminedichloroplatinum(II) (cis-DDP), 5-fluorouracil (5-FUra), and X-rays on growth inhibition of human pulmonary cancer nodules maintained in continuous organotypic culture was tested. To obtain the most effective growth inhibition, a cis-DDP treatment had to be preceded by an X-irradiation, whereas a 5-FUra treatment had to be postirradiated. This indicates the importance of the order in which the different combinations must be done. A mixture of 5-FUra and cis-DDP was even more effective than the X-ray and drug combination but only for a short period of time; reduction of nodule size and cell loss occurred during the 2 weeks following the treatment. After this period, as happened also with nodules treated with 5-FUra alone, vigorous regrowth occurred after treatment with cis-DDP plus 5-FUra, and all the nodules regained the size of the controls sooner or later. It is to be noted that, if X-rays were applied after a 5-FUra treatment, this regrowth is inhibited at least up to 45 days after the treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-fluorouracil.

Authors:  J F Belliveau; M R Posner; G W Crabtree; A B Weitberg; M C Wiemann; F J Cummings; G P O'Leary; E Ingersoll; P Calabresi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Adriamycin uptake and metabolism in organotypic culture of A549 human adenocarcinoma cells according to the exposure time.

Authors:  S Chevillard; P Vielh; G Bastian; J Coppey
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.